Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
This study has been completed.
Study NCT00102141   Information provided by Bayer
First Received: January 21, 2005   Last Updated: July 6, 2009   History of Changes

January 21, 2005
July 6, 2009
April 2004
 
  • Mean change in systolic office blood pressure measured at through [ Time Frame: After 8 weeks of treatment ]
  • Mean change in 24-hour systolic ambulatory blood pressure measurement (ABPM) [ Time Frame: After 8 weeks of treatment ]
Mean change from Baseline to Week 8 in systolic office blood pressure measured at trough and in 24-hour systolic ambulatory blood pressure measurement (ABPM) blood pressure.
Complete list of historical versions of study NCT00102141 on ClinicalTrials.gov Archive Site
  • Mean change in diastolic blood pressure measured at through [ Time Frame: After 8 weeks of treatment ]
  • Mean changes in 24-hour diastolic ABPM [ Time Frame: After 8 weeks of treatment ]
  • Mean change in daytime systolic ABPM [ Time Frame: After 8 weeks of treatment ]
  • Mean change in daytime diastolic ABPM [ Time Frame: After 8 weeks of treatment ]
  • Mean change in nighttime systolic ABPM [ Time Frame: After 8 weeks of treatment ]
  • Mean change in nighttime diastolic ABPM [ Time Frame: After 8 weeks of treatment ]
  • Mean change in systolic APBM at through [ Time Frame: After 8 weeks of treatment ]
  • Mean change in diastolic APBM at through [ Time Frame: After 8 weeks of treatment ]
Mean change from Baseline to Week 8 in diastolic office cuff blood pressure measured at trough and in 24-hour diastolic ABPM blood pressure.
 
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17ß-Estradiol 1 mg, Drospirenone 2 mg /17ß-Estradiol 1 mg, Drospirenone 1 mg /17ß-Estradiol 1 mg) Combinations and 17ß-Estradiol (1 mg) With Placebo for a Treatment Period of 8 Weeks on Ambulatory and Office Cuff Blood Pressure in Postmenopausal Women With Stage 1 or Stage 2 Essential Hypertension

The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.

Phase III
Interventional
Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Factorial Assignment, Safety/Efficacy Study
  • Hypertension
  • Postmenopause
  • Drug: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
  • Drug: Placebo
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
1879
August 2005
 

Inclusion Criteria:

  • Have hypertension
  • Are currently taking antihypertensive medications
  • Have had natural menopause at least 1 year prior to screening
  • Must require hormone therapy in the opinion of the investigator
Female
45 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00102141
Therapeutic Area Head, Bayer Healthcare Pharmaceuticals Inc.
91202, 306743
Bayer
 
Study Director: Bayer Study Director Bayer
Bayer
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP